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Abstract
MATERIALS ANDMETHODS: The genomic effects of tumor-endothelial interactions in cancer are not yet well char-
acterized. To study this interaction in breast cancer, we set up an ex vivo coculture model with human benign and
malignant breast epithelial cells with endothelial cells to determine the associated gene expression changes using
DNA microarrays. RESULTS: The most prominent response to coculture was the induction of the M-phase cell
cycle genes in a subset of breast cancer cocultures that were absent in cocultures with normal breast epithelial
cells. In monoculture, tumor cells that contained the stem cell–like CD44+/CD24− signature had a lower expres-
sion of the M-phase cell cycle genes than the CD44−/CD24+ cells, and in the CD44+/CD24− cocultures, these
genes were induced. Pretreatment gene expression profiles of early-stage breast cancers allowed evaluating
in vitro effects in vivo. The expression of the gene set derived from the coculture provided a basis for the segre-
gation of the tumors into two groups. In a univariate analysis, early-stage tumors with high expression levels (n =
137) of the M-phase cell cycle genes had a significantly lower metastasis-free survival rate (P = 1.8e − 5, 50%
at 10 years) and overall survival rate (P = 5e − 9, 52% at 10 years) than tumors with low expression (n = 158;
metastasis-free survival, 73%; overall survival, 84%). CONCLUSIONS: Our results suggest that the interaction of
endothelial cells with tumor cells that express the CD44+/CD24− signature, which indicates a low proliferative
potential, might explain the unexpected and paradoxical association of the CD44+/CD24− signature with highly
proliferative tumors that have an unfavorable prognosis.
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Introduction
Tumor angiogenesis is a prerequisite for tumor progression and metasta-
sis. It is a complex process that requires cooperative reciprocal interaction
of tumor cells and endothelial cells [1–4] and, thereby, offers an attractive
therapeutic target [5]. Clinical trials with antiangiogenic agents, such as
bevacizumab, which is an antibody against vascular endothelial growth
factor (VEGF), introduced these agents into clinical practice [6]. During
the last several years, antiangiogenic therapies, in combination with con-
ventional chemotherapeutic agents, have been established for different
tumor types, such as colorectal cancer [7], non–small cell lung cancer
[8], renal cell cancer [9], and breast cancer [10]. The average clinical
benefit of these drugs, however, is relatively modest, and it is unclear
which patients benefit the most. Improvements are likely to come from
a more thorough understanding of the molecular and cellular mecha-
nisms that govern tumor-endothelial cell interactions. Tumor angiogene-
sis involves a plethora of soluble and cellular components that interact
in a process of mutual signaling [11]. This requires a coordinated expres-
sion of proangiogenic factors [12] and suppression of antiangiogenic
factors [13], which leads to endothelial cell proliferation and migration
and vessel formation. Although multiple single genes have been de-
scribed in numerous reports to be involved in angiogenesis, such as
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growth factors [12,14], membrane-bound molecules [15], and extra-
cellular matrix components [16], there are likely others that have
remained unidentified. The interplay between the various factors and
their combined effects in tumor angiogenesis, however, remains to be
further characterized.
Carcinomas are not merely aggregates of malignant epithelial cells
but are, in many respects, organlike structures that include host
stromal cells, such as fibroblasts, adipocytes, inflammatory cells, and
the cells that form the tumor vasculature, and the malignant cells
themselves that intermingle and interact with all of these cell types
[17]. During the last few years, there has been growing evidence that,
besides the cellular processes within the tumor cells, a relevant con-
tribution to tumor progression is provided by the cells of the tumor
microenvironment [18]. On the molecular level, genome-scale gene
expression studies of many different carcinomas have illustrated in de-
tail the complexity of the tumors and the diversity of the associated
non–epithelial cell types [19]. Inductive interactions between these dif-
ferent cell types can play not only a morphogenetic role but also an
important mechanistic role in the pathogenesis and progression of
malignancy. The endothelial cells have so far been mainly viewed in
the context of vessel formation to improve the blood supply of the
tumor. However, relatively little is known about the paracrine effects
of these tumor-endothelial cell interactions. It was commonly thought
that the formation of new vessels would mainly be important for the
transport of nutrients and oxygen to the tumor cells and that inter-
rupting this support is the key mechanism of antiangiogenic therapies.
If we assume that, by the interruption of the vascular support, the
tumor gets more hypoxic, it seems paradoxical that antiangiogenic
therapies enhance the effects of chemotherapy and radiation. In the
hypoxic environment, these therapies have usually been shown to be
less effective [20]. However, the effects of these agents could be due,
in good part, to the disruption of the paracrine tumor-promoting sig-
naling that occurs as a result of the interaction of the cancer and endo-
thelial cells. Such reciprocal inductive signaling has been well known
from developmental biology and has again attracted special attention
with the concept of cancer stem cells and their stem cell niche [21].
Therefore, characterizing heterotypic cell-cell interaction effects on
a global gene expression scale might help to better understand the
currently used antiangiogenic agents and eventually lead to the iden-
tification of novel targets that could be used to interrupt these paracrine
stimulatory signaling pathways. This study specifically focuses on the
interaction between breast cancer cells and endothelial cells to identify
their reciprocal signaling effects.
Breast cancer is a heterogeneous disease, which implies that the tumor-
endothelial cell interactions might also be diverse. Tumor-endothelial
cell interactions are not yet well characterized on a genome-wide scale,
and they have not been compared between different tumor subtypes.
Toward this aim, we performed a systematic analysis of the interactions
between well-characterized breast cancer cell lines and primary endo-
thelial cells in coculture.
We have recently used the approach of in vitro coculture experiments
to characterize heterotypic interaction effects with DNA microarrays to
systematically describe the global-scale effects that the tumor-fibroblastic
stroma interaction has on gene expression. We identified a strong induc-
tion of an interferon response by specific tumor cells in coculture with a
diverse set of fibroblasts, which corresponded to a subset of breast cancers
with an unfavorable prognosis in vivo [22].
In this study, we used breast cancer cell lines and endothelial cells
for systematic coculture experiments, which allowed the interaction
effects to be characterized on a global gene expression scale. Using this
system, we investigated the following hypotheses:
1. The interaction of tumor and endothelial cells leads to changes
in gene expression, which are important for angiogenesis and tu-
mor progression. The gene expression programs that are involved
provide hints for the signaling mechanisms that are involved.
2. The interaction of tumor and endothelial cells leads to the in-
duction of gene expression signatures that are clinically rele-
vant. These interaction effects might account for a significant
proportion of the unexplained information in the gene ex-
pression data from tissue specimens. Given the evidence that
interactions between cells can play critical roles in tumor pro-
gression, these data might be even more meaningful than
prominent expression patterns, which are driven by the propor-
tional representation of a given cell type in a tissue.
We have performed a systematic overview of heterotypic interaction
effects of breast cancer and endothelial cells. The picture we obtained is
complex, but our results suggest that the interaction of endothelial cells
with a subset of CD44+/CD24− breast cancer cell lines induces a sig-
nature of “tumor-endothelial cell–induced M-phase cell cycle” genes,
which is associated with a worse outcome in human breast cancer.
Materials and Methods
Cell Culture
Human mammary epithelial cells (HMECs; Cambrex Bio Science
Walkersville, Walkersville, MD) were expanded in mammary epithelial
basal medium that was supplemented with bovine pituitary extract,
human epidermal growth factor, insulin, and antibiotics (Clonetics,
Cambrex Bio Science Walkersville). MCF-7, T47D, MDA-MB-231,
SKBR-3, Hs578T, and BT549 (ATCC, Atlanta, GA) were propagated
in Dulbecco’s modified Eagle medium that was supplemented with
10% FBS (HyClone, Logan, UT), glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin (Gibco, Grand Island, NY). Human
umbilical vein endothelial cells (HUVECs; ATCC) and human der-
mal microvascular endothelial cells (HDMECs; Cambrex Bio Science
Walkersville) were expanded in endothelial basal medium 2 (EBM2;
Cambrex Bio Science Rockland, Rockland, ME) that was supplemented
with human epidermal growth factor, hydrocortisone, GA-1000 (genta-
micin, amphotericin-B), 5% FBS, VEGF, human fibroblast growth
factor-B (with heparin), R3-IGF, and ascorbic acid. For the coculture
experiments, the cells were cultivated for 48 hours at an equal density
of 50,000 cells/cm2 (25,000 tumor cells/cm2 and 25,000 endothelial
cells/cm2) in endothelial basal medium (Cambrex Bio Science Rockland)
supplemented with 0.2% FBS. This medium served as a good universal
medium for all the cells in the study.
Proliferation Assays
Direct cell counting. For cell counting, prestarved cells were plated
in quadruplicate in 24-well plates at a density of 50,000 cells/cm2.
After 24 and 48 hours, the cells were trypsinized and resuspended in
0.2 ml of FACS buffer that contained 0.5% BSA and 2 mM EDTA
in PBS. The total cell number was determined using a cell counter.
WST-1 assay. The proliferation reagent 4-[3-(4-iodophenyl)-2-(4-
nitro-phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1; Roche
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Diagnostics GmbH, Roche Applied Science, Mannheim, Germany) was
used according to the manufacturer’s instructions. WST-1 is changed
by mitochondrial enzymes of metabolically active cells to a colorful
formazan that can be measured at a wavelength of 450 nm. The cell
number was determined by comparison of the absorbance values to a
standard cell dilution curve.
Comparison of HUVECs Proliferation in Response to
Different Conditioned Medium
To obtain the conditioned medium, 10e6, Hs578T,MDA-MB-231,
MCF-7, or HUVECs were extensively washed to avoid transfer of any
stimuli from the regular cell growth medium. The cells were kept in
10 ml of EBM2 that contained 0.2% FBS for 24 hours. The medium
was then aspirated and filtered through a 0.2-nm pore filter. In paral-
lel, 3000 HUVECs per well were plated in a 96-well plate and starved
for 24 hours in EBM2 that contained 0.2% FBS. For the stimulation
experiments, HUVECs were washed once with PBS and incubated for
48 hours in 1:2 diluted conditioned medium in EBM2 that contained
0.2% FBS. EBM2 that contained 0.2% FBS was used as a negative
control (vehicle medium), HUVEC culture supernatant that was di-
luted 1:2 in vehicle medium was used as an autologous medium con-
trol, and the full endothelial cell growth medium 2 that contained 5%
FBS and all the supplements that were described above was used as a
positive control. To determine the cell growth in response to stimula-
tion with conditioned medium, the cells were stained with 7% WST-1
in low-serumDulbecco’s modified Eagle medium (0.2% FBS) for 1 hour
at 37°C in 5% CO2. The absorbance was measured with an ELISA
reader at a wavelength of 450 nm. Values for each experimental condi-
tion were obtained by calculating the average of at least eight indepen-
dent replicates.
Inhibition with the Blocking Antibody Bevacizumab
To block the stimulatory effects of tumor cell conditioned media, the
medium was supplemented with 100 ng/ml bevacizumab (Avastin;
Genentech/Roche). To control the effect of bevacizumab, an additional
HUVEC culture was set up with a medium that was enriched with re-
combinant VEGF-A (5 ng/ml) and 5% FBS. The cell growth was de-
termined as above, and the absolute absorbance values were compared.
To check if blocking is specific for bevacizumab, trastuzumab
(Herceptin; Genentech/Roche) was included at equal concentrations
(0, 360, 720 ng/ml) in the analysis. As a negative control, HUVECs
that were treated with Hs578T cell culture supernatant were used.
The cell growth was determined as described before, and the absolute
absorbance values were compared.
RNA Isolation and Amplification
After discarding the culture medium and washing the cell layer once
with PBS, total RNA was isolated by lysing the cells in the culture
dish with RLT buffer (Qiagen, Valencia, CA) and extracting with the
RNeasy Mini Kit (Qiagen). Five hundred nanograms of total RNAwas
amplified using the Message Amp II aRNA Kit (Ambion, Austin, TX).
The amplification product was checked for integrity by electrophoresis
in a 1% agarose gel in MOPS buffer.
Complementary DNA Microarrays and Hybridization
The human complementary DNA (cDNA) microarrays contained
40,700 elements, which represented 24,472 unique genes that were
based on Unique Clusters. The arrays were produced at the Stan-
ford Functional Genomic Facility. Complete details regarding the clones
on the arrays may be found at: http://www.microarray.org/sfgf/jsp/
servicesFrame.jsp#productionArrays.
cDNA produced from 6 μg of amplified RNA were hybridized to
the array in a two-color comparative format, with the experimental
samples labeled with one fluorophore (Cy5) and a reference pool of
messenger RNA (Universal Human Reference mRNA; Stratagene,
La Jolla, CA) labeled with a second fluorophore (Cy3). The fluo-
rescent dyes were purchased from Amersham Pharmacia Biotech
(Piscataway, NJ). Hybridizations were carried out using the standard
protocol that was described previously [19].
Data Analysis and Clustering
Array images were scanned using an Axon Scanner 4000B (Axon
Instruments, Union City, CA), and image analysis was performed
using GenePix Pro version 5.0 3.0.6.89 (Axon Instruments). The raw
data files were stored in the Stanford Microarray Database [23], and the
data that were used for the article are available at: http://microarray-
pubs.stanford.edu/tumor-endothelial interaction. Data were expressed
as the log2 ratio of fluorescence intensities of the sample and the refer-
ence for each element on the array.
The (Cy5/Cy3) ratio is defined in the Stanford Microarray Database
[23] as the normalized ratio of the background-corrected intensities.
Spots with aberrant measurements that were due to obvious array arti-
facts or poor technical quality were manually flagged and removed
from further analysis. A filter was applied to omit measurements where
the fluorescent signal from the DNA spot was less than 50% above the
measured background fluorescence that surrounded the printed DNA
spot in either the Cy3 or the Cy5 channel. Genes that did not meet
these criteria for at least 80% of the measurements across the experi-
mental samples were excluded from further analysis. Valid data were
filtered to exclude elements that did not have at least a three-fold de-
viation from the mean in at least two samples. Data were evaluated by
unsupervised hierarchical clustering [24] and significance analysis of
microarray [25] and were displayed using TreeView (http://rana.lbl.
gov/EisenSoftware.htm).
GO::Termfinder
GO::TermFinder comprises a set of object-oriented Perl modules for
accessing Gene Ontology (GO) information and evaluating and visu-
alizing the collective annotation of a list of genes to GO terms [26]. It
can be used to draw conclusions from microarray and other biologic
data by calculating the statistical significance of each annotation.
Determination of the Heterotypic Interaction Effect on
Gene Expression
To facilitate the identification of heterotypic interaction effects on
global gene expression in a mixed coculture experiment, the gene ex-
pression data were normalized based on the proportional contribution
of each cell type to transcript abundance. Given that the average gene
does not change because of the heterotypic interaction and that there
are simple additive effects to account for, a linear regression fit was used
for normalization. To determine the contribution of each cell type to
the combined gene expression pattern in the linear regression model,
the expression levels of the monocultures were the predictors, and the
expression levels of the coculture were the response.
Specifically, a set of equations (1 − n) was established (one per gene):
en
coculture = ((a × en
monoculture1) + ((1 − a) × enmonoculture2)) × In, where e
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represented the expression level of the gene, a represented the pro-
portional contribution of mRNA from the respective monoculture,
n represented the number of genes measured on the microarray, and
I represented the interaction coefficient. We assume that the average
gene is not influenced by the heterotypic interaction in the mixed co-
culture, which is represented as I = 1. Because the data set over e1 − n
is skewed, a linear regression fit was empirically identified based on
Gamma errors and identity link as a good model to calculate a. The
equation 1 − n can then be solved for I1 − n, which results in a pro-
file of interaction effects for the genes1 − n. These interaction effects
can be analyzed in much the same way as conventional gene expres-
sion measurements.
Human Breast Cancer Data Set
The data set for breast cancer contained 295 tumors that were
analyzed on a 25,000-spot oligonucleotide array [27]. In brief, pa-
tients were diagnosed and treated at the Netherlands Cancer Institute
(NKI) for early-stage breast cancer (stages I and II) between 1984 and
1995. The clinical data were updated in January 2005. The median
follow-up for patients who are still alive is 12.3 years.
The “tumor-endothelial cell–induced M-phase cell cycle” gene list
consists of 98 genes that are represented by 95 image clones on the cDNA
Stanford Array. Clones having the same Unigene locus were removed.
The gene sequences were mapped to spots on the NKI array using
Unigene build no. 184 (released on June 9, 2005) to give 36 unique spots.
To overcome possible overweighting of clones from Unigene clusters
that were matched to more than one probe on the NKI array, expression
values that were derived from probes that were not matched to the
same Unigene cluster were averaged. Expression measurements for each
gene were mean centered. The resulting data set was subjected to hierar-
chical clustering with average linkage clustering [24] and displayed with
TreeView (http://rana.lbl.gov/EisenSoftware.htm).
Distant metastasis was analyzed as first event only (distant metastasis-
free probability). If a patient developed a local recurrence, an axillary
recurrence, a contralateral breast cancer, or a second primary cancer
(except for nonmelanoma skin cancer), he/she is censored at that time
and the subsequent distant metastases are not analyzed. This is based on
the theoretical possibility that the locally recurrent or second primary
cancers could be a source for distant metastases. An ipsilateral supra-
clavicular recurrence was soon followed by a distant metastasis in all
but one patient. An ipsilateral supraclavicular recurrence was thus con-
sidered to be the first clinical evidence for metastatic disease for this
analysis, and patients were not censored at the time of ipsilateral supra-
clavicular recurrence. Overall survival was analyzed based on death from
any cause, and patients were censored at last follow-up. Kaplan-Meier
survival curves were compared by the Cox-Mantel log-rank test using
Winstat for Microsoft Excel (R Fitch Software, Staufen, Germany).
A data set of gene expression patterns from advanced breast cancers
was described by Sorlie et al. [28]. Expression data from 53 image
clones that represented the “tumor-endothelial cell–induced M-phase
cell cycle” gene list were included in this data set. Genes and samples
were organized by hierarchical clustering. Relapse-free and overall sur-
vivals were calculated as described above.
Centroid Correlation
The method of calculating the centroid for each patient was pre-
viously described by Sorlie et al. [28]. The centroids were profiles
that consisted of the average gene expression value for each of the
patients. Briefly, the centroids for the genes that represented the
“tumor-endothelial cell–induced M-phase cell cycle” signature as well
as the other signatures were calculated based on the NKI data set. To
test a similarity between the signatures, the correlation between values
of different centroids was checked for each patient. The correlation
was calculated using the Pearson correlation coefficient with R soft-
ware [29].
Results
Setup of a Tumor-Endothelial Coculture Model
As a model for investigating the gene expression program in re-
sponse to epithelial-endothelial interactions in the normal breast
and in breast cancer, cells that represented either benign or malig-
nant epithelial cell compartments and cells that represented endothe-
lial cell compartments were examined in an in vitro mixed coculture
setting. The cells were cocultivated for 48 hours in low-serum me-
dium (0.2% FBS) to allow reciprocal signal exchange with minimal
background from the influence of undefined molecular signals that
are inherent in fetal bovine serum. We examined the effects of co-
cultivation for each cell pair in two independent biologic replicates.
The gene expression profiles of the cocultures were compared with
the expression profiles of the corresponding cells that were kept in
monoculture using cDNA microarrays that contained approximately
40,700 elements representing 24,472 unique Unigene clusters (build
no. 173, released on July 28, 2004). To establish this experimental
approach, we first focused our experiments on the breast cancer cell
line, Hs578T, the dermal microvascular endothelial cell, HDMEC,
and the coculture of these two cell types. The data passing our data
quality filter, a filter for data distribution and a filter selecting genes
that are more consistent within replicate samples than between ex-
perimental samples, were organized using unsupervised hierarchical
clustering of the replicate experiments to provide an overview of the
effects on global gene expression (Figure 1A). In the coculture, most
genes displayed intermediate expression levels, which closely approxi-
mated the proportionally weighted average of their expression levels
in the two cell types in monoculture. Despite setting up the cocul-
ture with equal cell numbers of Hs578T and HDMEC, the gene
expression pattern after cocultivation is dominated by the pattern of
Hs578T. However, one set of genes showed a consistent increase in
transcript abundance in the coculture when compared with either
monoculture, which suggested that the induction of these genes was
an effect of cocultivation.
Interestingly, 11% of the 44 genes within this gene set are involved
in DNA replication as determined by GO terms, and they are RRM2,
Cdc45L, MCM4, KIAA1212, and MCM8 [26] (Appendix Figure 1).
The frequency of the genes that were involved in this function is
significantly enriched (P = .006) compared with the background of
1140 genes passing the data quality and data distribution filters as
shown in the heat map of Figure 1. Furthermore, several genes are
involved in the cell cycle, and they are CCNA2, RAD54B, AURKA,
and CENPN. STC1, which is an extracellular matrix protein found
in breast cancer [30] and known to be involved in angiogenesis [31],
was also detected in this set of genes. Taken together, these gene sets
suggest proliferation of the tumor-endothelial cell coculture.
Because breast cancer is a clinically and molecularly heterogeneous
disease, we selected a broad spectrum of different breast cancer cell lines
to sample this heterogeneity and explore the effects of a heterotypic
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culture by looking for subtype-specific and shared response patterns.
The focus was on epithelial-endothelial cell interactions, which were
studied by cocultivating endothelial cells of different origins (HUVEC
and HDMEC) in combination with HMECs or six widely used breast
cancer cell lines. HDMECs, which are a commercially available dermal
microvascular endothelial cell line, were selected to resemble the tumor
vasculature endothelial cells of breast cancer as accurately as possible.
HUVECs were selected to represent venous cells, despite the fact that
the umbilical and breast environments are different. However, the
changes that were observed suggest the system works well.
The changes in gene expression that are due to heterotypic inter-
actions were subtle when compared with the large intrinsic variation in
expression patterns among the involved cell types, as illustrated in
Figure 1A for the cell pair of Hs578T and HDMEC. To identify the
gene expression changes that resulted from cell-cell interactions, it was
necessary to control for the simple additive effects that reflect the pro-
portional contribution of the two cell types to the total population of
each gene’s transcript in coculture. Elimination of these proportionally
weighted additive contributions allowed the isolation of supra-additive
interaction effects. The fact that the transcript levels of most genes did
not change in response to coculture allowed a linear regression model
that was based on the transcription profiles of each monoculture be
fitted to the coculture data for normalization. An example of this type
of analysis is shown in Figure 1B. For each gene, the ratio of the mea-
sured transcript level and the level that was estimated by the linear
model provides a measure of the heterotypic interaction effect. This
is illustrated in Figure 1C , which shows the distribution of the gene
expression changes of the Hs578T/HDMEC coculture. The genes that
Figure 1. Effect of heterotypic interaction between an endothelial cell and a breast cancer cell line. (A) Biologically independent repli-
cates of the monocultured HDMEC, the breast cancer cell line Hs578T, and the mixed coculture of HDMEC and Hs578T were grown for
48 hours at low serum conditions and characterized by DNA microarray hybridization. Hierarchical clustering of a total of 1140 elements
that display a greater than three-fold variance in expression in more than two different experimental samples. Data from individual ele-
ments or genes are represented as single rows, and different experiments are shown as columns. Red and green denote the expres-
sion levels of the samples. The intensity of the color reflects the magnitude of the deviation from baseline. Unsupervised hierarchical
clustering of the experiments grouped the biologic replicates together. Gene expression varied considerably between HDMEC and
Hs578T cultures as expected for cells of mesenchymal or epithelial origin, respectively. The coculture profile showed mainly inter-
mediate expression levels. However, the vertical black bar marks a cluster of genes that were induced in all cocultures when compared
with both monocultures, which indicated that they were induced by the heterotypic interaction. Zooming in on the genes that were
upregulated in coculture revealed that they were specific for proliferation and mitosis. (B) Correlation of the measured coculture gene
expression levels and their estimated expression levels based on the proportional contribution of each cell type as determined by a linear
regression fit of the monoculture to the coculture data. (C) Fold change of each gene that was associated with coculturing of HDMEC and
Hs578T. Genes of the “proliferation and mitosis” cluster are indicated in red. Dashed lines indicate 95% confidence limits.
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were identified by hierarchical clustering as differentially expressed in
coculture when compared with monoculture are highlighted to illus-
trate the performance of this approach. Interaction effects, which are
represented as gene expression changes, are converted to quantitative
values that can be analyzed for similarities and disparities over multiple
different pairwise interactions between cells with the same tools that
are used to analyze conventional gene expression data.
There was an obvious heterogeneity in the responses of different
pairs of cells to cocultivation (Figure 2). A striking feature was a cluster
of genes that was induced in MDA-MB-231 and Hs578T cocultures
with either HUVEC or HDMEC but not in the cocultures with the
HMECs. To test for enrichment in a specific functional gene ontology,
we applied again the GO::Termfinder tool and found that this set of
104 genes was highly enriched for genes associated with the M-phase
of the cell cycle compared with the background of 8140 genes (P =
1.87e − 16). This set of “tumor-endothelial cell–induced M-phase cell
cycle” genes included TOP2A, CDC2A, CCNB2, DHFR, CIT, TK1,
CCNA, RRM2,NUSAP1,TPX2,CDC25C,CENPA,CENPE, AURKA,
DTL, DICER, WHSC1, PSIP1, and MTPN. Interestingly, WHSC1
plays a role in tumorigenicity, adhesion, and clonogenic growth in mul-
tiple myeloma [32]; PSIP1 [33], which is a transcriptional coactivator
that is involved in different processes, plays a protective role in stress
induced apoptosis; and MTPN [34] is a gene that belongs to the myo-
trophin family.
Differential Induction of Proliferation with Conditioned
Medium from Different Tumor Types
As implied by the higher expression of the “tumor-endothelial cell–
induced M-phase cell cycle” gene signature, the proliferation rate, as
determined by direct cell counting over time, was significantly higher
in the coculture of Hs578T and HUVEC than in isolated Hs578T
or HUVEC cultures (Figure 3A). Also, by flow cytometric cell cycle
analysis using propidium iodine staining, we observed a higher propor-
tion of cells leaving the G1 phase in the coculture than in the mono-
cultures indicative of a higher proportion of cells cycling and passing the
M-phase (data not shown).
We speculated that specific factors secreted by the tumors might
increase the growth of the endothelial cells or vice versa. Toward this
aim, we reciprocally incubated one cell type in conditioned medium
from the other cell type. In fact, when the conditioned medium from
the HUVECs is applied to the tumor cells, the tumor cells show a
significantly higher proliferation rate than when kept in autologous
medium as measured by the increase in relative cell numbers using
the WST-1 proliferation assay (P = 1.3e − 12 [MCF-7], P = 4.6e −
06 [Hs578T], P = 4.3e − 07 [MDA-MB-231], unpaired 2-sided
t test; Figure 3B). This explains the enhanced proliferation, but it
does not explain the differences in proliferation between cocultures
of the distinct tumor subtypes. Of note, the conditioned medium from
HUVECs induced a higher level of proliferation in MCF-7 cells than
in either MDA-MB-231 or Hs578T cells. However, when the condi-
tioned media that are derived from the different tumor types are applied
to HUVECs, there is an increase in proliferation on stimulation with
conditioned medium from Hs578T cells, which is not seen in the
response to the supernatant from MCF-7 cells (Figure 3C). This pat-
tern of differential induction is consistent with the differences in the
expression of the “tumor-endothelial cell–induced M-phase cell cycle”
gene signature, which was observed in the cocultures of Hs578T or
MCF-7 in combination with HUVECs.
Figure 2. Gene expression changes in multiple cocultures of breast
cancer cell lines with endothelial cells. Overview of collapsed data
from repeat coculture experiments of eight benign and malignant
epithelial cells with two different endothelial cells (HUVEC and
HDMEC). The 9 monocultures and the 14 cocultures were analyzed
independently in duplicates on 46 HEEBO arrays. Raw data were fil-
tered for technical quality as described in Materials and Methods
section, leaving 37,773 spots. A data distribution filter eliminating
spots with a log2-based red-green normalized ratio of less than 1 in
at least two arrays removed 10,183 suid(s), leaving 27,590. Genes
with missing data in more than 20% of the arrays were removed,
leaving 14,565. On the basis of this data set, the calculation of the
interaction factors was performed for all 14 cocultures separately
as described in Materials and Methods section. The interaction fac-
torswere then further analyzed for their distribution, and factors with
an SD of less than 0.5 were eliminated, leaving interaction factors
for 8140 genes, which are shown as a heat map after unsupervised
hierarchical clustering. Red and green denote relative changes in
expression that were associated with heterotypic interaction. The
magnitude of the relative change is given by color intensity. Zooming
in on a cluster of genes that was consistently upregulated in more
than two of the cocultures revealed that they were specific for the
M-phase of the cell cycle.
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Differential Pattern of Secreted Factors in the Tumor Subtypes
We speculated that the induction of the “tumor-endothelial cell–
induced M-phase cell cycle” genes in cocultures of Hs578T and
MDA-MB-231 is due to cell-cell signaling of factors that are specifi-
cally expressed at higher levels in these cells. To systematically identify
these molecules, a two-class significance analysis of microarray data was
performed [25], with one class formed by Hs578T and MDA-MB-
231 and the other by HMEC, HDMEC, HUVEC, BT549, SKBR3,
T47D, and MCF-7. Among the genes that were expressed at signifi-
cantly higher levels in these two cell types were several inducers of
angiogenesis, which included VEGFC, FGF12, PTN, and NF1. There
were also several transcription factors that were coexpressed with these
genes, such as SNAI2 and ZFHx1B, which are known to be involved
in the epithelial-mesenchymal transition. Interestingly, the PDGFB re-
ceptor, which responds to PDGFB that is secreted by endothelial cells,
was found in these cells (Figure 4A). The full list of genes is given in
Appendix Table 1.
Expression of CD44/CD24 in the Diverse Cells
Because breast cancer cells that have the potential to influence the
cells within their microenvironment in a way that enhances prolifera-
tion might have stem cell characteristics, we speculated that the tumor
cells that expressed these angiogenic factors might carry the CD44+/
CD24− stem cell–like signature, as previously described [35]. Figure 4B
shows the relative expression of the mRNA of these two antigens in
the breast cancer cell lines as measured on the cDNA microarray.
CD44 is consistently upregulated in the breast cancer cells that induced
the M-phase cell cycle genes in the coculture with endothelial cells,
whereas CD24 is consistently downregulated.
This led us to the following working model: Tumor cells first se-
crete endothelial stimulatory signals, such as VEGF, FGF12, PTN, and
NF1 (Figure 4C). On stimulation, the endothelial cells start to express
PDGFB, which then signals back to the tumor cells through the up-
regulated PDGFB-R. This feedback loop is facilitated by matching pairs
of receptors and ligands, and the coculture starts proliferating.
Blocking Hs578T-Induced Proliferation of HUVEC
with Bevacizumab
One of the best described signaling pathways of endothelial cell pro-
liferation is the VEGF pathway [12]. This pathway can be specifically
blocked by bevacizumab, which is amonoclonal antibody against VEGF
[36]. Whereas Hs578T induces the “tumor-endothelial cell–induced
M-phase cell cycle” gene signature in cocultivation with HDMEC,
the expression level of this signature in the coculture of MCF-7 and
HDMEC represents just the average of the two cells in monoculture
(Figure 5A). In accordance with these observations, bevacizumab is
able to specifically block the stimulatory effect of Hs578T conditioned
medium on HUVECs, whereas there was no significant effect on
HUVECs that were incubated with conditioned medium that was de-
rived fromMCF-7 (Figure 5B). Bevacizumab, in contrast to trastuzumab,
which served as a negative control, was able to block the conditioned
medium that was derived fromHs578T cells and resulted in a reduction
in proliferation of HUVECs by approximately 50% to 80%, depending
on the antibody concentration (Figure 5C). This supports the VEGF
pathway as an important factor that enhances tumor-endothelial cell
proliferation. However, it is not sufficient alone to explain the full effect.
Other factors that were identified by differential expression analysis in
our coculture model might also be involved and, therefore, represent
valuable targets for therapeutic intervention.
In Vivo Effects of the “Tumor-Endothelial Cell–Induced
M-Phase Cell Cycle” Gene Signature
We investigated the effect on global gene expression in response to
heterotypic cell-cell interaction as a simple, controlled, ex vivo model
of tumor-endothelial cell interaction. We reasoned that identifying and
characterizing gene expression programs that were characteristically in-
duced by the interaction between specific pairs of cells in culture might
enable us to recognize and interpret specific features in the expression
profiles of human cancers that represent similar interactions between
Figure 3. Proliferation of tumor and endothelial cells is due to recip-
rocal stimulation. (A) Proliferation of HUVECs and Hs578T monocul-
tures and their 1:1 coculture as determined by measuring the
increase in cell number by direct cell counting after 36 hours. (B)
Box-and-whisker diagrams of relative cell numbers of MCF-7,
Hs578T, and MDA-MB-231 after incubation with conditioned me-
dium from HUVECs compared with a normalized negative control
of the same cells incubated with autologous medium as measured
by the colorimetric cell proliferation assay with the WST-1 com-
pound. (C) Proliferation of HUVECs that was induced by conditioned
medium from Hs578T and MCF-7 cells as measured by WST-1. Rel-
ative absorbance values of colorful formazan, which has been con-
verted by HUVECs, correspond to relative cell numbers. A single
column represents average absorbance values for a minimum of
eight independent replicates. y Axis error bars correspond to SD.
The HUVECs that were treated with the Hs578T supernatant grew
significantly faster than the same cells that were treated with the
MCF-7 supernatant, the fresh vehicle medium, or the autologous
(HUVEC-derived) medium.
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tumor and endothelial cells in vivo. The most consistent response to
ex vivo cocultivation of breast cancer and endothelial cells was the
induction of “tumor-endothelial cell–induced M-phase cell cycle”
genes. We, therefore, looked for this response in the expression patterns
in the published data from 295 early-stage (stages I and II) breast can-
cer samples from the NKI [27]. The “tumor-endothelial cell–induced
M-phase cell cycle” genes showed a strikingly coherent variation in
expression among these cancers, which enabled these cancers to be di-
vided into two groups. One group had a relatively high expression and
the other had a relatively low expression of the “tumor-endothelial cell–
induced M-phase cell cycle” genes. Clustering the breast carcinomas
based only on the expression of the “tumor-endothelial cell–induced
M-phase cell cycle” genes separated them into two main clusters, with
one cluster having a high-level expression of most of the “tumor-
endothelial cell–inducedM-phase cell cycle” genes and the other having
a lower expression of these genes (Figure 6A). The same coordi-
nated behavior and segregation of tumors could be observed in a dif-
ferent set of advanced breast cancer samples [28,37], which suggested
that variation in this “tumor-endothelial cell–induced cell M-phase
cell cycle” program is a general feature in breast cancer (Appen-
dix Figure 2).
As a first assessment of its potential biologic relevance, distant
metastasis-free survival and overall disease-specific survival were com-
pared between the two groups. Early-stage tumors with high expression
Figure 4. Genes associated with the tumor-endothelial induced M-phase cell cycle gene signature. (A) Significance analysis of micro-
array data to identify genes that show the largest expression differences between tumor cells that were inducing a proliferation re-
sponse in coculture with the cells and those that were not inducing proliferation. The expression levels of the top 63 genes are shown
on a heat map after unidimensional hierarchical clustering of the genes. (B) Relative expression of CD44 and CD24 in diverse breast cancer
cell lines. The average expression of their mRNA over the cell lines corresponds to 0. (C) Working model of reciprocal tumor-endothelial
signaling based on the higher expression in the cocultures that induced proliferation.
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levels (n = 137) of this particular gene set had a significantly lower dis-
tant metastasis-free survival (P = 1.8e − 5; 50% at 10 years) and overall
survival rate (P = 5e − 9; 52% at 10 years) than tumors with low ex-
pression levels (n = 158; metastasis-free survival, 73% at 10 years; over-
all survival, 84% at 10 years; Figure 6B).
The same trend toward unfavorable outcome in patients with
cancers that showed high levels of “tumor-endothelial cell–induced
M-phase cell cycle” gene transcripts (P = .17) could be seen in the
analysis of the data set from advanced-stage breast cancers [28] (data
not shown) from Norway/Stanford.
Correlation to Other Prognostic Gene Expression Signatures
The relationship between the “tumor-endothelial cell–induced
M-phase cell cycle” gene signature and three previously identified gene
expression signatures, which were useful prognosticators in this data set,
were also investigated (Figure 7). The first signature is a set of 70 genes
[38], which was identified in a supervised analysis of a subset of the
NKI early-stage breast cancer data set [27], that could predict freedom
from metastasis at 5 years. The second signature was identified in vitro
by exposing fibroblasts to serum to mimic a wound response, and it
has been shown to predict a risk of progression [39]. The “tumor-
endothelial cell–induced M-phase cell cycle” gene signature seems to
be highly correlated with the poor prognosticator wound (0.605) sig-
nature and to be the reciprocal of the good prognosticator 70-gene
signature (−0.708), which indicated that our hypothesis that was based
Figure 5. Stimulatory effect of Hs578T conditioned medium on en-
dothelial cells can be partially blocked by bevacizumab. (A) Rela-
tive expression of the “tumor-endothelial cell–induced M-phase
cell cycle” genes in different monocultures of breast cancer cell
lines and endothelial cells and in their respective cocultures. (B)
Blocking of the stimulatory effect of Hs578T conditioned medium
by bevacizumab. Absolute absorbance values of formazan dye that
was converted by HUVECs, which corresponds to cell numbers,
are shown in columns, with the y axis bars corresponding to SD.
Bevacizumab (100 ng/ml) depleted the stimulatory effect of Hs578T
cell culture supernatant in a significant manner, whereas it had no
effect on the MCF-7 cell culture supernatant. Recombinant VEGF-A
(5 ng/ml) and 5% FBS served as positive and negative controls,
respectively. (C) Dose-dependent blocking of HUVEC proliferation
by bevacizumab and trastuzumab. Absolute absorbance values of
formazan dye that was converted by HUVECs are shown. HUVECs
that were treated with the Hs578T cell culture supernatant repre-
sent the baseline stimulatory effect. Bevacizumab depleted the
stimulatory effect of the Hs578T conditioned medium in a signifi-
cant, dose-dependent manner. Trastuzumab, which is a monoclonal
antibody against HER2, did not influence HUVEC stimulation by the
Hs578T conditioned medium.
Figure 6. “Tumor-endothelial cell–inducedM-phase cell cycle”genes
in early-stage breast cancer. (A) The expression values of genes in
the “tumor-endothelial cell–induced M-phase cell cycle” gene signa-
ture were extracted from a published expression study of 295 early-
stage breast cancers from the Netherlands Cancer Institute [35].
Genes and samples are organized by hierarchical clustering. The
tumors were segregated into two groups that were defined by
high (red) or low (blue) expression levels of the 30 genes matching
the M-phase cell cycle gene cluster. (B) Correlation of the “tumor-
endothelial cell–induced M-phase cell cycle” gene signature status
with distant metastasis-free and overall survival. Kaplan-Meier
curves for the clinical outcomes of the indicated tumors that exhibit
high (red curve) and low (blue curve) “tumor-endothelial cell–induced
M-phase cell cycle” gene signature expression are shown.
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on an in vitro model is of in vivo clinical relevance. Interestingly, the
“tumor-endothelial cell–induced M-phase cell cycle” gene signature
has even a higher correlation to the 70-gene profile, which was derived
as a prognosticator by a top down analysis of this exact data set, than the
wound signature. The invasiveness gene signature, which was derived
from a comparison of CD44+/CD24− stem cell–like cells with normal
breast epithelial cells, predicted poor prognosis in breast cancer [40].
This signature, despite having similar prognostic power as the wound
signature, did not correlate well with the 70-gene signature, with the
wound signature, or with the “tumor-endothelial cell–inducedM-phase
cell cycle” gene signature (−0.21).
Discussion
The main objective of this study was to examine and characterize the
effects of heterotypic cellular interaction to gain insight into the under-
lying biology of these effects in normal mammary tissue and in breast
cancer, with a specific focus on the interaction between epithelial tumor
cells and endothelial cells. To isolate specific, direct interactions from
more complex interactions that involve multiple cell types in a whole
tissue or organism, we used a simple ex vivo coculture model. Because
some important heterotypic interactions might require direct cell-cell
contact, we focused on a coculture model where the two cell types were
mixed [22]. In this report, we describe the systematic genomic analysis
Figure 7. Correlation to other prognostic gene signatures in early-stage breast cancer. Correlation of the 70-gene signature [50], the wound
signature [49], the invasiveness gene signature [40], and the “tumor-endothelial cell–induced M-phase cell cycle” signature score in the NKI
data set. Pairwise scatter plot matrix of the three gene signatures. Pearson correlations are shown in the lower part of each plot.
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of this simple in vitro system that simulates direct and indirect inter-
actions between benign and malignant epithelial cells and endothelial
cells in normal breast tissue and in breast cancer.
Common Gene Set Induced by Tumor-Endothelial Coculture
As expected, based on our experience with the tumor-fibroblast inter-
action [22], the picture of heterotypic interaction effects from the survey
of diverse tumor cells with two different types of endothelial cells is
complex and reflects the different abilities of normal and malignant cells
to send and respond to extrinsic signals. Our data show that the effects
of the tumor-endothelial cell interaction differ between different breast
cancer cell lines that each represents a different breast cancer subtype.
A prominent theme in our coculture experiments was a set of genes that
were characteristic of the mitotic phase of the cell cycle, which we called
the “tumor-endothelial cell–induced M-phase cell cycle” gene expres-
sion signature. This observation on the gene expression level is consis-
tent with the phenotypic features that show a higher proliferation rate
in the respective cocultures. In our setting, the mere coexistence of two
cell types of different origin, such as the Hs578T breast cancer cells and
endothelial cells, seems to be sufficient to induce proliferation. Co-
operate induction between cells of different lineages is well known from
developmental biology, where stem cells cooperate with their environ-
mental cells to form the stem cell niche. The stem cell concept has also
been introduced in cancer [41]. Cells with stem cell characteristics have
been prospectively isolated from breast cancer using CD44 and CD24
as markers [35]. From these cells, which are characterized as CD44+/
CD24−, a prognostic gene expression signature has been determined,
which has been called the invasiveness signature [40]. This signature
has been associated with an unfavorable prognosis in breast cancer.
However, it was unclear how that small fraction of stem cells could lead
to such a prominent gene expression pattern in the genomic profile of
breast cancer, and it was unexpected that a signature that was derived
from stem cells, which are known for their low proliferative potential,
was linked to the highly proliferative, poor prognostic tumors.
Hs578T and MDA-MB-231 both exhibit the CD44+/CD24−
phenotype. Whereas in monoculture under low serum conditions, they
proliferated slowly in a manner that was similar to stem cells [42,43],
in coculture with endothelial cells, they had a high proliferation rate
along with associated changes in gene expression. This induction of
proliferation markers is absent in the cocultures with CD44−/CD24+
cells. Therefore, cocultivation of endothelial cells with breast cancer
cells links the CD44+/CD24− signature with high proliferation, which
is then associated with the overexpression of the “tumor-endothelial
cell–induced M-phase cell cycle” gene signature and predicts a poor
prognosis in breast cancer. We are well aware that the CD44+/CD24−
signature is preferentially associated with basal type carcinomas, in
contrast to the CD44−/CD24+ signature, which is associated with the
luminal-type breast cancer cells [44]. In this context, the cocultivation
with endothelial cells explains the worse prognosis of basal type breast
cancer despite the lower proliferation rate of the isolated basal-type
breast cancer cells in monoculture. This exemplifies that this simple
in vitro coculture model is more similar to the in vivo situation than
the monoculture. The stem cell–like cells with highly potent tumor-
initiating properties, as they were described by Al-Hajj et al. [35], clearly
exhibited the CD44+/CD24− signature but were also characterized by
additional markers. It has been shown that CD44+/CD24−–expressing
cell lines contain these tumor-initiating cells [42,45], but, of note, we
did neither specifically focus on nor explicitly select for these stem
cell–like cells.
Differences Are Due to Differential Endothelial
Cell Proliferation
A comparison of the gene expression program between the CD44+/
CD24− tumor cells that upregulate the “tumor-endothelial cell–
induced M-phase cell cycle” genes and the CD44−/CD24+ tumor
cells that do not reveals multiple genes that seem to be involved in
angiogenesis. This gene subset includes VEGF, FGF, and other endo-
thelial stimulatory factors. Many genes in this cluster are functionally
less well described, although they might be involved in tumor cell
proliferation or in the induction of tumor angiogenesis. To demon-
strate their functional impact, we blocked VEGF with bevacizumab,
which is a specific antibody against VEGF. A good part of the stimu-
latory effect of Hs578T conditioned medium on HUVECs was abro-
gated with bevacizumab. This demonstrates that these genes play a
considerable functional role and are not just surrogate markers that
are associated with faster tumor growth. Whereas VEGF partially
blocks the effects of the tumor cell supernatant, other factors might
also contribute to endothelial proliferation and thereby represent pos-
sible additional new therapeutic targets. Most notably, these additional
factors could be responsible for drug resistance to anti-VEGF mono-
therapy if tumors start using these alternative angiogenic factors to grow
blood vessels.
With consideration to the cancer stem cell concept, the stem cell
niche has been proposed to play an important role in carcinogenesis
and progression, although it remains largely uncharacterized at the cel-
lular and molecular levels. It is possible to speculate that endothelial
cells participate in the breast cancer stem cell niche. In a mouse model,
VEGFR+ bone marrow–derived cells have been shown to form a stem
cell niche for cancer cells, and such cells have been identified in human
breast cancer biopsies [46]. In brain cancer, stem cells were demon-
strated to live in a vascular niche that secretes factors that promote their
long-term growth and self-renewal [47]. The factors that we have
described to enhance the proliferation of Hs578T, a CD44+/CD24−–
expressing cell line, which contains at least in part stem cell–like cells
[42] and endothelial cells, might also be involved in a breast cancer stem
cell niche. We are well aware that the endothelial cells of the vascular
system are diverse [48] and that the tumor vasculature consists of spe-
cifically altered endothelial cells. The endothelial cells that we selected,
which were the HUVECs and HDMECs, do not represent the autolo-
gous tumor vasculature endothelial cells of breast carcinomas. We can,
therefore, not exclude the possibility that endothelial cells that are
isolated from within a tumor might show additional specific interaction
effects. Nevertheless, it would be surprising if carcinoma-associated
endothelial cells failed to show the strong effects that we consistently
observed in cocultures with HUVECs and HDMECs. Because these
experiments might be insufficient to detect subtle differences between
cocultures that involve different types of tumor-endothelial cells, a
more specific selection of primary tumor-associated endothelial cells
would be needed in the optimal case in cocultivation with primary
tumor cells.
Predictive Marker for Antiangiogenic Drugs
We have shown that the “tumor-endothelial cell–induced M-phase
cell cycle” signature is a strong prognostic signature that strongly cor-
relates with other prognostic signatures such as the wound signature [49]
and the 70-gene signature [27]. A subset of the genes that are found
in our signature overlaps with a subset of the genes that are found in
the “wound signature,” which was characterized by the stimulation of
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fibroblasts with serum, resembling the response of fibroblasts to wound-
ing. Our situation also resembles the situation of wounding, where
new vessels have to spread to the wound area to nourish the new wound
fibroblasts. The 70-gene signature is currently studied in prospective
clinical trials to spare some women chemotherapy without risking their
chance of cure [50]. For clinical decisionmaking, it is important to define
biomarkers that could serve as predictive factors about the benefit of
certain therapies, especially in the case of new therapeutic options, such
as antiangiogenic drugs. So far, there is no valid biomarker for this pur-
pose. Although there is evidence from preclinical studies, we have to
be cautious when extrapolating preclinical data to the human disease.
Preclinical experiments are often designed to look at the influence of
well-defined biologic phenomena on drug efficacy. By contrast, human
disease ismore complex andmight requiremultiplemarkers to accurately
predict efficacy. For this purpose, a set of in vitro–designed biomarkers,
which are already independently tested for their prognostic power, such
as our “tumor-endothelial cell–induced M-phase cell cycle” gene signa-
ture or the associated set of angiogenesis-inducing factors, could serve as
potential predictors that are worth further evaluation.Our in vitromodel,
which involves the mere coculture of two cell types, seems to allow the
identification of a strongly prognostic gene signature. Whereas the genes
from the 70-gene signature have not yet been associated with a single
functional ontology, our signature is linked to a mechanistic in vitro
model that allows for further experimentation.
In our previous work, we have modeled the interaction of tumor cells
with fibroblasts, which allowed us to define an interferon response gene
set [22]. In this work, we have characterized a tumor-endothelial cell
interaction. It would be interesting to see how different carcinoma-
associated fibroblasts and endothelial cells interact and how the addition
of tumor cells would reprogram the system. Our coculture technique
may allow us to further explore these more complex interactions among
the multiple molecules that operate in these cells to orchestrate the pro-
cess of cancer progression and metastasis. Our experience suggests that
in vitro modeling of specific processes and features of the tumor micro-
environment can provide a valuable interpretive framework for the
analysis of associated gene expression patterns in more heterogeneous
in vivo samples and the identification of the effects of heterotypic cel-
lular interactions.
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Appendix
Appendix Figure 1. GO terms. Graphical visualization of the output from GO::Termfinder for process ontology: GOgraph layout that
includes the significant GO nodes annotated by DNA replication, derived from 44 clones from a background of 1140. The color of the nodes
is an indication of their Bonferroni corrected P value (orange ≤ 1e− 10; yellow = 1e − 10 to 1e−8; green = 1e−8 to 1e−6; cyan = 1e−6
to 1e−4; blue = 1e−4 to 1e−2; tan > 0.01).
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Appendix Table 1. List of Genes Expressed in Breast Cancer Cell Lines Inducing Proliferation in Coculture.
CLID UniGene Cluster ID ∣∣ Symbol ∣∣ Gene Name
IMAGE:754582 ∣∣ Hs.567266 ∣∣ NF1 ∣∣ Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease)
IMAGE:280699 ∣∣ Hs.563491 ∣∣ EPDR1 ∣∣ Ependymin related protein 1 (zebrafish)
IMAGE:138991 ∣∣ Hs.233240 ∣∣ COL6A3 ∣∣ Collagen, type VI, alpha 3
IMAGE:878836 ∣∣ ∣∣ ∣∣ ∣∣ AA670429 ∣∣ ∣∣ ∣∣ IMAGE:878836 ∣∣ 110839
IMAGE:45138 ∣∣ Hs.435215 ∣∣ VEGFC ∣∣ Vascular endothelial growth factor C
IMAGE:1031532 ∣∣ Hs.226780 ∣∣ OSTM1 ∣∣ Osteopetrosis associated transmembrane protein 1
IMAGE:460002 ∣∣ Hs.269027 ∣∣ GALNT5 ∣∣ UDP-N -acetyl-alpha-D-galactosamine:polypeptide N -acetylgalactosaminyltransferase 5 (GalNAc-T5)
IMAGE:204737 ∣∣ Hs.360174 ∣∣ SNAI2 ∣∣ Snail homolog 2 (Drosophila)
IMAGE:1913366 ∣∣ Hs.128013 ∣∣ PRSS3 ∣∣ Protease, serine, 3 (mesotrypsin)
IMAGE:898218 ∣∣ Hs.450230 ∣∣ IGFBP3 ∣∣ Insulin-like growth factor binding protein 3
IMAGE:489519 ∣∣ Hs.297324 ∣∣ TIMP3 ∣∣ TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory)
IMAGE:489089 ∣∣ Hs.474053 ∣∣ COL6A1 ∣∣ Collagen, type VI, alpha 1
IMAGE:488404 ∣∣ Hs.27621 ∣∣ ∣∣ Clone TUA8 Cri-du-chat region mRNA
IMAGE:753587 ∣∣ Hs.167741 ∣∣ BTN3A3 ∣∣ Butyrophilin, subfamily 3, member A3
IMAGE:857640 ∣∣ Hs.420269 ∣∣ COL6A2 ∣∣ Collagen, type VI, alpha 2
IMAGE:1030805 ∣∣ Hs.458623 ∣∣ ∣∣ Transcribed locus, moderately similar to XP_509196.1 PREDICTED: similar to FTO protein [Pan troglodytes]
IMAGE:868212 ∣∣ Hs.369397 ∣∣ TGFBI ∣∣ Transforming growth factor, beta-induced, 68 kDa
IMAGE:2545711 ∣∣ Hs.592971 ∣∣ ∣∣ Transcribed locus
IMAGE:1470128 ∣∣ Hs.411391 ∣∣ LOC399959 ∣∣ Hypothetical gene supported by BX647608
IMAGE:121981 ∣∣ Hs.419240 ∣∣ SLC2A14 ∣∣ Solute carrier family 2 (facilitated glucose transporter), member 14
IMAGE:1893136 ∣∣ Hs.596112 ∣∣ ∣∣ Transcribed locus ∣∣ AI278518 ∣∣ ∣∣ ∣∣ IMAGE:1893136 ∣∣ 313617
IMAGE:753467 ∣∣ Hs.419240 ∣∣ SLC2A14 ∣∣ Solute carrier family 2 (facilitated glucose transporter), member 14
IMAGE:789147 ∣∣ Hs.511915 ∣∣ ENO2 ∣∣ Enolase 2 (gamma, neuronal)
IMAGE:299539 ∣∣ Hs.584758 ∣∣ FGF12 ∣∣ Fibroblast growth factor 12
IMAGE:471196 ∣∣ Hs.111577 ∣∣ ITM2C ∣∣ Integral membrane protein 2C
IMAGE:504761 ∣∣ Hs.374774 ∣∣ ANKRD29 ∣∣ Ankyrin repeat domain 29
IMAGE:811000 ∣∣ Hs.514535 ∣∣ LGALS3BP ∣∣ Lectin, galactoside-binding, soluble, 3 binding protein
IMAGE:153646 ∣∣ Hs.172928 ∣∣ COL1A1 ∣∣ Collagen, type I, alpha 1
IMAGE:897768 ∣∣ Hs.476218 ∣∣ COL7A1 ∣∣ Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)
IMAGE:263716 ∣∣ Hs.474053 ∣∣ COL6A1 ∣∣ Collagen, type VI, alpha 1
IMAGE:269425 ∣∣ Hs.34871 ∣∣ ZFHX1B ∣∣ Zinc finger homeobox 1b
IMAGE:754106 ∣∣ Hs.297324 ∣∣ TIMP3 ∣∣ TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory)
IMAGE:809719 ∣∣ Hs.477128 ∣∣ CCDC80 ∣∣ Coiled-coil domain containing 80
IMAGE:1558164 ∣∣ Hs.89901 ∣∣ PDE4A ∣∣ Phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog, Drosophila)
IMAGE:293339 ∣∣ Hs.360174 ∣∣ SNAI2 ∣∣ Snail homolog 2 (Drosophila)
IMAGE:291290 ∣∣ Hs.558402 ∣∣ SSX4 ∣∣ Synovial sarcoma, X breakpoint 4
IMAGE:609332 ∣∣ Hs.409662 ∣∣ COL14A1 ∣∣ Collagen, type XIV, alpha 1 (undulin)
IMAGE:239256 ∣∣ Hs.173859 ∣∣ FZD7 ∣∣ Frizzled homolog 7 (Drosophila)
IMAGE:210717 ∣∣ Hs.1501 ∣∣ SDC2 ∣∣ Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan)
IMAGE:415122 ∣∣ Hs.48384 ∣∣ HS3ST3B1 ∣∣ Heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1
IMAGE:625234 ∣∣ Hs.642759 ∣∣ KDELR3 ∣∣ KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3
IMAGE:843222 ∣∣ Hs.210283 ∣∣ COL5A1 ∣∣ Collagen, type V, alpha 1
IMAGE:234736 ∣∣ Hs.514746 ∣∣ GATA6 ∣∣ GATA binding protein 6
IMAGE:80643 ∣∣ Hs.482730 ∣∣ EDIL3 ∣∣ EGF-like repeats and discoidin I-like domains 3
IMAGE:502689 ∣∣ Hs.632387 ∣∣ NEXN ∣∣ Nexilin (F actin binding protein)
IMAGE:109424 ∣∣ Hs.103110 ∣∣ PPARA ∣∣ Peroxisome proliferative activated receptor, alpha
IMAGE:813823 ∣∣ Hs.406475 ∣∣ LUM ∣∣ Lumican
IMAGE:110503 ∣∣ Hs.480712 ∣∣ LARP2 ∣∣ La ribonucleoprotein domain family, member 2
IMAGE:1475595 ∣∣ Hs.75431 ∣∣ ALPL ∣∣ Alkaline phosphatase, liver/bone/kidney
IMAGE:742125 ∣∣ Hs.65436 ∣∣ LOXL1 ∣∣ Lysyl oxidase-like 1
IMAGE:510729 ∣∣ Hs.437040 ∣∣ PTPN21 ∣∣ Protein tyrosine phosphatase, non-receptor type 21
IMAGE:769686 ∣∣ Hs.643513 ∣∣ THY1 ∣∣ Thy-1 cell surface antigen
IMAGE:144916 ∣∣ Hs.62661 ∣∣ GBP1 ∣∣ Guanylate binding protein 1, interferon-inducible, 67 kDa
IMAGE:345849 ∣∣ Hs.102267 ∣∣ LOX ∣∣ Lysyl oxidase
IMAGE:502664 ∣∣ Hs.35861 ∣∣ TMEM158 ∣∣ Ras-induced senescence 1
IMAGE:786265 ∣∣ Hs.501928 ∣∣ MICAL2 ∣∣ Microtubule associated monoxygenase, calponin and LIM domain containing 2
IMAGE:590759 ∣∣ Hs.105269 ∣∣ SC4MOL ∣∣ Sterol-C4-methyl oxidase-like
IMAGE:854678 ∣∣ Hs.567598 ∣∣ LBH ∣∣ Hypothetical protein DKFZp566J091
IMAGE:344272 ∣∣ Hs.9999 ∣∣ EMP3 ∣∣ Epithelial membrane protein 3
IMAGE:361974 ∣∣ Hs.371249 ∣∣ PTN ∣∣ Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)
IMAGE:1593317 ∣∣ Hs.509067 ∣∣ PDGFRB ∣∣ Platelet-derived growth factor receptor, beta polypeptide
IMAGE:756372 ∣∣ Hs.438823 ∣∣ KCNH2 ∣∣ Potassium voltage-gated channel, subfamily H (eag-related), member 2
IMAGE:415134 ∣∣ Hs.632256 ∣∣ STAT5B ∣∣ Signal transducer and activator of transcription 5B
Genes that are differentially expressed between breast cancer cell lines inducing the “tumor-endothelial cell–induced M-phase cell cycle” gene signature contain multiple endothelial growth factors.
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